Last reviewed · How we verify
A-101 Topical Solution 40%
A-101 Topical Solution 40% is a topical solution used to treat hyperhidrosis.
A-101 Topical Solution 40% is a topical solution used to treat hyperhidrosis. Used for Treatment of primary axillary hyperhidrosis.
At a glance
| Generic name | A-101 Topical Solution 40% |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Drug class | Anticholinergic |
| Target | M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
It works by reducing sweat gland function, thereby decreasing sweat production. The exact mechanism of action is not fully understood, but it is believed to involve the reduction of sympathetic nervous system activity in the sweat glands.
Approved indications
- Treatment of primary axillary hyperhidrosis
Common side effects
- Dry mouth
- Headache
- Dizziness
Key clinical trials
- Study of A-101 for the Treatment of Seborrheic Keratosis (PHASE2)
- A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra (PHASE2)
- An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (PHASE4)
- Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis (PHASE2)
- Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis (PHASE1, PHASE2)
- A Study of A-101 Solution in Subjects With Common Warts. (PHASE2)
- An Open-Label Safety Study of A-101 Solution (PHASE3)
- A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |